AI assistant
GILEAD SCIENCES, INC. — Director's Dealing 2013
Jul 17, 2013
29828_dirs_2013-07-17_00b5920b-9fff-4992-91c2-f9b0d9b2c7b2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GILEAD SCIENCES INC (GILD)
CIK: 0000882095
Period of Report: 2013-07-15
Reporting Person: BISCHOFBERGER NORBERT W (EVP, R&D and CSO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2013-07-15 | Common Stock | M | 90000 | $14.5025 | Acquired | 2249643 | Direct |
| 2013-07-15 | Common Stock | S | 90000 | $57.3348 | Disposed | 2159643 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2013-07-15 | Non-Qualified Stock option (right to buy) | $14.5025 | M | 90000 | Disposed | 2016-01-25 | Common Stock (90000) | Direct |
Footnotes
F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
F2: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
F3: Sale prices reported for the transactions reported here range from $56.83 to $57.62. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.